lifestyle.longislandreport.org

MEDIPAL HOLDINGS and JCR Pharmaceuticals Sign Global Licensing and Japan Co-Development Agreement for JR-479, a Novel Therapy for GM2 Gangliosidosis

Written by

businesswire

MEDIPAL HOLDINGS and JCR Pharmaceuticals Sign Global Licensing and Japan Co-Development Agreement for JR-479, a Novel Therapy for GM2 Gangliosidosis – NEWSnet – News… as it used to be


More Press Releases